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ABSTRACT The Paediatric Assembly of the European Respiratory Society (ERS) maintained its high profile
at the 2015 ERS International Congress in Amsterdam. There were symposia on preschool wheeze, respiratory
sounds and cystic fibrosis; an educational skills workshop on paediatric respiratory resuscitation; a hot topic
session on risk factors and early origins of respiratory diseases; a meet the expert session on paediatric lung
function test reference values; and the annual paediatric grand round. In this report the Chairs of the
Paediatric Assembly’s Groups highlight the key messages from the abstracts presented at the Congress.
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ADVANCES IN AMSTERDAM
PAEDIATRICS
Early life risk factors for wheezing and asthma
There is increasing interest in exposure during pregnancy and even prior to conception on the risk of
childhood respiratory diseases [1]. LODGE et al. [2] investigated the association between grand-maternal
smoking at 10–12 weeks of pregnancy and asthma risk in grandchildren using data from Swedish
registries. Children had a 6–22% increased risk of asthma during the first 6 years of life if their
grandmothers smoked during early pregnancy, independent of maternal smoking. These findings support
possible epigenetic transmission of risk from environmental exposures in previous generations. In a
cross-sectional study, PESCE et al. [3] reported that children exposed to maternal vaginitis in pregnancy
were more likely to have had bronchitis, pneumonia and wheezing in the first 2 years of life, and current
asthma at 6 years of age. However, as the researchers themselves acknowledge, these data should be
confirmed in a prospective study in order to avoid recall bias and misclassification. Use of paracetamol in
pregnancy has been repeatedly reported to be associated with wheezing and asthma in the first years of life
[4], but the problem of confounding by indication has also been raised [5]. MAGNUS et al. [6] explored the
issue in the Norwegian Mother and Child Cohort and concluded that although there is evidence of
confounding by indication this does not fully explain the association between paracetamol use only during
pregnancy and asthma at 3 and 7 years of age in the offspring. As for early post-natal factors associated
with wheezing and asthma, living on farms has been shown to protect children from asthma and allergies.
A major factor involved in this effect is the consumption of unprocessed cow’s milk [7]. Within the
Pasture Study Group, which includes children living in rural areas in five European countries, samples of
the milk usually consumed were taken at the age of 4.5 years [8], while doctor-diagnosed asthma was
parent-reported at age 6 years. The risk of asthma was reduced when consuming raw farm milk as
compared with shop milk. Part of the effect was attributable to the content of omega-3 fatty acids, which
could counterbalance the synthesis of pro-inflammatory leukotrienes and prostaglandins. Accumulating
evidence suggests an association between early growth patterns and wheezing in infancy. Within the
NINFEA birth cohort, POPOVIC et al. [9], using a novel modelling approach (SITAR) that allows for mutual
adjustment of different aspects of growth, showed that larger size and faster growth over the first
18 months of life, but not the timing of peak weight velocity, were independently associated with an
increased risk of wheezing at 18 months of age.
Asthma and allergy: genetics and environment
The asthma risk locus 17q21 modifies the effects of smoking and early viral infections on subsequent
asthma [10]. LOSS et al. [11] of the Pasture Study Group followed children in rural areas of several countries
in Europe from birth until 6 years of age. Single nucleotide polymorphisms (SNPs) in the genes ORMDL3
and GSDMB at locus 17q21 were assessed in cord blood. Exposures to siblings or to animal sheds affected
wheezing largely in carriers of known asthma risk alleles. LOSS et al. [11] conclude that the 17q21 locus
might be related both to environmental susceptibility and to progression from wheeze to asthma. The
associations between traffic-related air pollution (TRAP), asthma and allergies in children are
heterogeneous; possibly due to genetic polymorphisms that modify the response to oxidative stress [12].
BOWATTE et al. [13] investigated if variants in the glutathione pathway alter associations between early life
TRAP exposure and childhood asthma and allergies in a high risk birth cohort of children in Australia.
Baseline TRAP exposure was not associated with any outcome. Carriers of GSTM1null and GSTT1null had
an increased risk of current asthma at 7 years and current eczema at 18 years of age. GSTT1null carriers
exposed to TRAP in early life had an increased risk of wheeze and asthma at 12 years of age when
compared with TRAP exposed carriers of wild-type GSTT1. Polymorphisms of CD14 are associated with a
lower risk of allergic disease in children, but little is known about the effects in adult life. LAU et al. [14]
aimed to examine if the association between CD14 polymorphisms and allergic sensitisation in middle age
was modified by sibling exposure in early life in participants from the Tasmanian Longitudinal Health
Study. Exposure to siblings at 6 months, 2 years and 4 years was associated with a significantly reduced risk
of allergic sensitisation. They showed evidence of CD14 SNPs and sibling interaction for allergic
sensitisation. The gene–environment interaction was strongest in the first 6 months of life, suggesting that
this may be a critical period for altering the risk of allergy.
European Respiratory Society task force on primary ciliary dyskinesia and beyond
Published data on primary ciliary dyskinesia (PCD), a rare disease leading to chronic airways inflammation
and infection, are scarce and often based on small case series. A consensus statement of a European
Respiratory Society (ERS) task force published in 2009 [15] concluded that the evidence base for diagnosis
and treatment of PCD is poor and more research is needed. Nasal nitric oxide (nNO) is currently
recommended as a screening tool. PANAJOTIS et al. [16] evaluated the diagnostic performance of nNO for
detection of PCD by examining 12 published studies and concluded that it has high overall diagnostic
accuracy. However, COLLINS et al. [17] using data from prospective referrals to the PCD service at University
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Hospital of Southampton, where the incidence of PCD is 11%, underlined that the very high negative
predictive value of the test (99.1%) makes nNO a good rule-out test, but the low positive predictive value
(26.3%) makes it a poor test for general screening. They calculated that screening the general population
would reduce the positive predictive value to 0.04%. Within the European project BESTCILIA, HALBEISEN
et al. [18] compared the lung function (forced expiratory volume in 1 s (FEV1)) of patients with PCD to the
Global lung function initiative (GLI) 2012 reference values and to published data from UK patients with
cystic fibrosis (CF) [19]. FEV1 was significantly reduced compared with normal reference values. As for the
comparison with CF data, FEV1 was similarly low in children (e.g. at age 6–9 years patients with PCD had a
FEV1 of 87% predicted, while in CF patients FEV1 was 90%); while in adults aged 18–21 years FEV1 was
better in PCD (76% predicted, 95% CI 73–80%) than in CF (66% predicted, 95% CI 65–68%).
Infant lung function
Objectively assessing lung function in infants remains one of the most challenging aspects of respiratory
physiology. For the most part measurements are performed following sedation, use complex equipment
and require highly trained staff [20, 21]. A recent survey on the clinical utility of infant lung function
testing shows that while many centres were using lung function tests in infants to aid in clinical decision
making there were many barriers to practical use [22]. One of these barriers was the availability of
appropriate reference values for the infant version of spirometry (the raised volume rapid thoracic
compression technique (RVRTC)). LUM et al. [23] reported reference values for modern commercial
RVRTC equipment ( Jaeger BabyBody; Care Fusion, San Diego, CA, USA) derived from data in
367 infants over 607 visits in four centres. Significant differences to the previously published RVRTC
reference equations were noted [24], suggesting that users of the Jaeger BabyBody RVRTC equipment
should adopt these new reference equations for their research and clinical RVRTC work.
Much of our understanding of lung growth and development has been derived from longitudinal
measurements of lung function in birth cohorts [25, 26]. However, the repeated measurement of infant
lung function tests is difficult. KOWALIK et al. [27] reported the feasibility of obtaining repeated multiple
breath washout (MBW), body plethysmography and RVRTC data (in that order) over the first 2 years of
life in the CHILD birth cohort. Of the three tests, MBW measurements had the highest feasibility at any
one visit (range: 79–98%), with body plethysmography (70–83%) and then RVRTC (49–56%) being
successively lower. In the 191 infants that attended more than one visit, longitudinal data was obtained in
63% of MBW attempts compared with 50% of body plethysmography and 33% of RVRTC assessments.
These data suggest that feasibility will be influenced by test order, further highlighting the importance of
consideration of the primary outcome in assessments of lung function in infancy. In a unique study, GRAY
et al. [28] reported longitudinal measurements of infant lung function in the Drakenstein birth cohort.
These investigators assessed lung function in unsedated infants at two time-points (6 weeks and 1 year).
Of the 507 eligible infants, data was obtained in 472 (93%) at 6 weeks and 377 (74%) at 1 year for at least
one lung function test. Paired tidal breathing or MBW outcomes were obtained in 234 and 209 infants,
respectively, representing over 50% of the tested infants. These results demonstrate for the first time that
unsedated measurements of some forms of infant lung function tests can be obtained longitudinally and
may assist in allowing more wide spread integration of lung function testing in this age group.
Lung function in older children
PFLEGER et al. [29] compared changes in spirometry and multiple breath nitrogen washout after cold dry
air challenge. In those children who had a positive challenge test the decrease in FEV1 and the increase in
lung clearance index (LCI) correlated well. Scond (ventilation heterogeneity in conducting airways) was a
predictor of airway hyperresponsiveness (AHR); exhaled nitric oxide fraction (FeNO) seemed to predict
airway AHR as well. This might be helpful in assessing AHR in young children. DE LEEUW et al. [30]
showed that most children with asthma have normal spirometry, even if they have severe asthma. LCI had
better discriminating power between severe and mild-to-moderate asthma; however, the vast majority of
children had a normal LCI, irrespective of asthma severity, which may limit the clinical utility of MBW
techniques in asthma. Two research groups reported data on a new lung function technique, structured
light plethysmography (SLP) [31–33]. SLP is a noninvasive, noncontact test that does not require
cooperation by the patient. It records real-time images of chest wall movement, using a grid of light on the
chest and abdomen of the patient, which is imaged by two cameras. With this technique data on breathing
pattern, the tidal breathing flow/volume graph, inspiratory or expiratory flow limitation, and regional
subdivision may be assessed. A group from Verona, Italy showed that with SLP expiratory flow limitation
could be detected in children with an acute asthma attack versus children with stable asthma [31].
Researchers from the UK assessed changes in tidal breathing parameters in children with acute asthma
and found significant differences before and after bronchodilation [32]. The same group collected
normative data on several parameters of SLP in healthy children [33]. This technique seems feasible in
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uncooperative children and as such may be useful in preschool children among others. It is obvious that
more studies on validity, reproducibility and usefulness in clinical practice are needed.
The onset of disease, during which time pathophysiological changes are subtle, offers challenges for the
identification and tracking of altered respiratory function in children. It is therefore imperative that the
most appropriate lung function test for any one specific lung disease is selected [34]. NYILAS et al. [35]
elegantly demonstrated this principle with an analysis of MBW outcomes in children with PCD, CF,
preterm children and healthy controls. They demonstrated that even within one technique not all outcomes
were altered. While preterm children tended to have normal MBW outcomes there were some differences in
the slope III values when using the novel double tracer gas variant of the MBW test. In contrast, children
with CF demonstrated altered lung clearance (LCI) and convection dependant ventilation distribution
(Scond), while children with PCD also had altered acinar ventilation when compared with healthy children.
Two studies reported longitudinal tracking of LCI and spirometry in children with CF, with both
demonstrating that measurements of lung clearance were more likely to deteriorate over time than
spirometry [36, 37]. While JAYASURIYA et al. [38] demonstrated that LCI was more likely to be abnormal (14
(58%) out of 24 children) compared with FEV1 (5 (21%) out of 24) in children following bone marrow
transplant, further reinforcing the importance of using the most appropriate test for each specific lung
condition. Several studies in children born preterm highlighted these concepts with varying degrees of
pathophysiology reported. BAR-YISHAY et al. [39] reported spirometry and forced oscillatory mechanics
before and after bronchodilator responsiveness in preterm children with and without bronchopulmonary
dysplasia (BPD). As reported previously [40], preterm children exhibited reversible obstruction; however,
the differences did not completely return to normal with lung function remaining lower in preterm
compared with term born children. In contrast to other data presented at the Congress (discussed later),
there were no differences in lung function between those children with and without BPD, which may be
attributed to sample size and/or differences in cohort characteristics. O’DEA et al. [41] reported that while
the majority of children (aged 9–11 years) born very preterm (<32 weeks completed gestation) had altered
lung structure on computed tomography (CT) this did not influence peak exercise capacity in these
children, which was not different to that of term born controls. It was, however, noted that dynamic flow
limitation during exercise was common in preterm children with BPD suggesting an altered response to
maximal exercise unrelated to exercise capacity. The same children were followed longitudinally with paired
lung function at 4–7 and 9–11 years [42]. As is commonly reported, preterm children with and without
BPD had lower spirometry that term controls [40]. Spirometry was noted to decline over time only in
preterm children with BPD with their mean±SD FEV1 reducing by −0.47±0.92 (p<0.02) z-scores. The
number of children with obstructive lung function (FEV1/forced vital capacity less than the lower limit of
normal) increased from 32 to 52%. The significance of these changes is not clear, but suggests an active
disease process in preterm children with BPD that requires detailed investigation.
LCI measured by MBW has already been shown to be a sensitive marker of CF lung disease, which is now
being be used as a surrogate outcome measure in clinical trials [43], as a surveillance tool to monitor
structural lung disease [44], and as a prediction tool for pulmonary exacerbations in children with CF
[45]. However, LCI response to therapy for pulmonary exacerbations is heterogeneous in CF patients, the
overall effect size is small and the results are often discordant with FEV1 [46]. A group from Toronto
presented their data on whether LCI can track disease progression: they observed an association between
known risk factors (10 or more antibiotic courses and the use of dornase alfa) and higher LCI values; they
also found better nutritional status was associated with lower LCI values [47]. An Australian group
presented more evidence that LCI may be a useful surveillance tool for early lung disease, demonstrating
LCI was higher in those with neutrophil activity in bronchoalveolar lavage (BAL), and in children infected
with multiple pathogens compared with uninfected subjects [48]. The London CF Collaboration showed
evidence that preschool LCI correlated with adolescent LCI (r=0.59, p<0.01) and adolescent FEV1 (r=0.48,
p<0.05), but there was no correlation between preschool and adolescent spirometry [49]. A comparison of
exercise testing with MBW and high resolution CT showed a higher sensitivity than spirometry in
detecting changes in CF lung disease [50]. However, there remain many open questions regarding the
optimal equipment and standardisation, for example which software and algorithms should be used to
calculate LCI and functional residual capacity from MBW [51, 52].
Sleep monitoring
The pathogenesis and treatment of sleep disorders in children are generally well understood; however, the
optimal treatment of obstructive sleep apnoea (OSA) and the potential impact of comorbidities is less
certain [53, 54]. DOMANY et al. [55] examined the rate of treatment failure in 659 children with
moderate-to-severe OSA. Children were assessed for residual OSA using a screening questionnaire
following either adenotonsillectomy, adenoidectomy or no treatment. Untreated children were twice as
likely (OR 2.02, 95% CI 1.26–3.51) to have ongoing OSA compared with children treated with
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adenotonsillectomy, while there were no differences between adenotonsillectomy and adenoidectomy
suggesting that adenoidectomy may offer additional treatment pathways for paediatric OSA. While
laboratory based sleep studies remain the gold standard for the diagnosis of sleep disorders, the cost and
availability remain barriers to their use. Options that allow the screening of children to minimise the
requirement for polysomnography (PSG) are urgently needed. VAN EYCK et al. [56] and WEBER et al. [57]
reported the potential of screening in children with OSA. VAN EYCK et al. [56] assessed the ability to
identify OSA in 130 obese children using nocturnal oximetry when compared with full PSG studies, and
reported poor sensitivity (58%) and specificity (88%) of oximetry concluding that oximetry alone was
insufficient to identify OSA in obese children. WEBER et al. [57] assessed the role of unattended PSG in 135
children over a 3-year period. Study failure was highest in the first year (52%) and dramatically decreased to
15% in the third year. The primary cause of failure was loss of sensor, which occurred more commonly in
younger children. While these data highlight the importance of training in these forms of studies, this study
confirms the benefits of unattended PSG in subgroups of patients. While the assessment and treatment of
airway inflammation is common in children with asthma, its role in children with sleep disorders is less
clear [58]. Studies presented at the 2015 ERS International Congress reported increased 8-isoprostane [59]
and leukotriene B4 [60] in children with OSA. SUPINO et al. [59] assessed 8-isoprostane from urinary and/or
exhaled breath condensate samples and matched PSG in 84 children with sleep disordered breathing.
Children with moderate-to-severe OSA had higher 8-isoprostane (median (interquartile range) 52.1
(39.2–100.6) pg·mL−1) than children with primary snoring only (31 (18.8–41.9) pg·mL−1; p<0.005) with
significant associations between 8-isoprostane and the apnoea–hypopnoea index (AHI) in children with
OSA. In contrast, ALEXOPOULOS et al. [60] found no relationships between leukotriene B4 and the AHI
(r=−0.11; p=0.26) or desaturation index (r=−0.13; p=0.21) in 104 children with confirmed sleep
disordered breathing. However, children with high leukotriene B4 (defined as >75th centile of leukotriene
B4 levels in healthy controls) were over three times more likely (adjusted OR 3.19, 95% CI 1.16–8.74;
p=0.02) to have tonsillar hypertrophy suggesting a link with upper airway inflammation and some aspects
of sleep pathogenesis in children.
Infection and inflammation in CF
Early diagnosis of pulmonary infection with Pseudomonas aeruginosa is necessary to enable timely
eradication therapy. However, this is particularly challenging in those who are unable to expectorate
sputum. Specific P. aeruginosa quorum sensing signal molecules have potential as biomarkers to aid
diagnosis of infection. In a prospective, multicentre observational study over 3 years, UK researchers found
a high sensitivity and specificity of such a molecule (2-heptyl-4-hydroxyquinoline (HHQ)) in plasma (86%
sensitivity and 86% specificity, respectively) and urine (79%, 71%) compared with conventional
microbiological culture [61]. In a longitudinal analysis of 45 children without P. aeruginosa infection at
baseline, plasma HHQ levels were significantly associated with subsequent positive culture during the
following year. The presence of fungi in the airways of patients with CF is common, but the pathogenic role
of most fungi is unclear. The most prevalent species are Aspergillus and Candida. Metagenomic studies
have opened a new dimension, and can identify a large population of fungal microbiota in CF, which are
usually not seen in cultures. In a Spanish, prospective, observational cohort study, metagenomic
investigations revealed 82% had fungi in contrast to none in culture [62]. In adults, metagenomic screening
increased the detection rate of fungi from 30% in culture to 70%; in most cases the fungi were Candida
(38%) and Aspergillus (11%). Patients with newly acquired fungal isolates had worse lung function when
compared with persistent culture-negative patients, suggesting that newly acquired isolates impact on
disease progression. A research group from Qatar reported a high prevalence of Candida dubliniensis (65%)
in the sputum of their CF patients. However, the clinical significance of their observation remains unclear
[63]. A retrospective data analysis of the UK registry in 2013 revealed an association of inhaled tobramycin
and colistin use with increased risk of both non-Aspergillus and Aspergillus fungal isolation, with odds
ratios of 1.33 and 1.40, respectively. In contrast to tobramycin use (with an OR 1.34), there was no
statistically significant association between colistin use and Aspergillus isolation [64]. Allergic
bronchopulmonary aspergillosis (ABPA) causes a high degree of morbidity due to its symptomatology, and
the side-effects of long-term corticosteroid therapy. A research team from Germany presented data on the
influence of domestic pets on ABPA acquisition. Pet owners showed a higher occurrence of clinical proven
ABPA (23%) compared with non-pet owners (8%), which was still highly significant after adjustment for
other variables in a multiple logistic regression analysis [65]. The Tel-Aviv CF Centre presented their
experience with Nocardia infection among 200 CF patients. Eight (4%) had at least one sputum sample
positive for Nocardia; half of whom had a mild course or no symptoms, however, the other half developed
severe lung disease, for which they recommend an early aggressive multidrug therapy [66].
Inflammatory markers are a potentially useful tool for monitoring lung disease in CF, but could only be
used routinely if they can be measured noninvasively. Researchers from the Australian AREST-CF study
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group measured metabolites from BAL using mass spectrometry, and found an association between
decreased levels of adenosine and its metabolite inosine as well as oxidised glutathione and CF lung disease
[67]. These data provide new insights into adenosine signalling pathways involved in airway inflammatory
responses, and have identified a number of metabolites associated with early disease that could potentially
serve as noninvasive biomarkers and therapeutic targets in early CF. In a study from the Netherlands, CF
exacerbations were best predicted by a set of nine volatile organic compounds (VOCs), provided that the
time interval between breath sampling and exacerbations was not longer than 7 days [68]. VOCs can also
be emitted by P. aeruginosa and Aspergillus fumigatus cultures, and their fingerprints are time dependent
and differ between mono-cultures and co-cultures, which complicates the in vivo determination [69]. Nitric
oxide plays an important role in the regulation of airway calibre and host defence against certain pathogens.
In CF airways, nitric oxide is reduced and may contribute to CF lung disease. The mechanisms resulting in
reduced airway nitric oxide formation in CF are not completely understood, but recent studies suggest a
direct link between cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction and low nitric
oxide production from nitric oxide synthases. Changes in FeNO may serve as a biomarker of restored CFTR
function in the CF lower airway during CFTR modulator treatment [70]. The effect of ivacaftor on airway
nitric oxide has been assessed for the first time by a Canadian research team. They measured FeNO before
and 4 weeks after initiation of ivacaftor therapy [71, 72]. In a total of 15 patients, pulmonary function
improved significantly and mean±SD FeNO increased from 8.5±5.0 to 16.2±15.5 ppb. The effect was more
pronounced in paediatric compared with adult patients, but there was no linear correlation between
changes in FeNO, pulmonary function or sweat chloride concentration.
A French group presented their research on histidinylated polylysines (pLK) and suggest pLK30-His8 as a
promising new alternative anti-inflammatory agent or mucolytic, as it is able to compact DNA and liquefy
sputum of CF patients [73]. The Catalonia CF newborn screening programme presented their results on
cascade carrier testing of relatives when a positive case was discovered [74]. All parents were identified as
heterozygous carriers of the corresponding mutation, with the exception of three parents who had, in
addition to the corresponding mutation, another CFTR mutation in trans. These three parents all had
pathological sweat tests (chloride 65–75 mmol·L−1) and mild symptoms, although they had normal lung
function. The authors believe this emphasises the benefits of genetic testing of parents for potential new
CF diagnoses, as well as informing genetic counselling for families. However, there are potential drawbacks
such as discovering non-paternity, which is a recognised issue in most countries.
There is ongoing controversy about the routine use of bronchodilators in CF. The effect of long-term
anticholinergic tiotropium bromide therapy in patients with CF has never been investigated. In a retrospective
study of 172 patients, subjects treated with tiotropium bromide for 24 months showed a significant difference
in mean annual change of FEV1 [75]. However, this difference was small (0.43±4.4% versus −2.2±5.18% in
controls), and tiotropium bromide therapy was not associated with a lower exacerbation risk. Nevertheless
clinical experience shows this can be useful in patients with intractable wheezing not responding to usual
combination therapy with inhaled corticosteroids and a long-acting β2-agonist.
Neonatology and intensive care
In a very recent Cochrane review, elective use of high frequency oscillatory ventilation (HFOV) was shown
to reduce the risk of BPD; however, lung mechanics during HFOV is still incompletely understood [76].
To elucidate this, two studies from the same research group evaluated the use of resonant frequency in
infants and demonstrated for the first time that non-uniform chest wall displacement decreased with
increasing oscillation frequency, but asynchronies became more evident [77, 78]. In a study by BHAT et al.
[79], lung mechanics during volume-targeted ventilation were compared with pressure-limited ventilation
in a group of term or near-term infants and found to be associated with fewer episodes of hypocarbia,
although not a reduction in the time to successful extubation. This is very similar to what has been
previously reported by the same group of researchers regarding preterm infants suggesting that, regardless
of gestational age, an important benefit of volume-targeted ventilation is reduction of the risk for
over-ventilation [80]. In a very elegant experimental study, BOURKE et al. [81] could visualise the response
to methacholine in a mouse model of BPD and using phase-contrast microscopy demonstrated an
excessive contraction in the small airways of lungs exposed to hyperoxia and perinatal inflammation. The
susceptibility to AHR in children with BPD is a clinical problem, with twice as many of former BPD
patients being asthmatic at school age [82]. This model holds the potential for further investigations of the
underlying mechanisms to reveal new targets for treatment of airway hyperreactivity in BPD.
Newborn infants, and particularly those born preterm, are at risk for apnoea due to immature
autoregulation of respiration; however, several factors may play a role and the following studies have
contributed to increased knowledge about the mechanisms behind apnoea in the newborn period. ROSSOR
et al. [83] have demonstrated an increased ventilatory response to hypercarbia in preterm infants receiving
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caffeine therapy. Contrary to this, term infants of smoking and substance abusing mothers exhibited a
dampened ventilatory response to hypercarbia, possibly contributing to an increased risk for sudden infant
death syndrome [84]. Finally, with the use of synchronised PSG and pH intraluminal impedance no causal
relationship between gastro-oesophageal reflux and apnoea could be shown in a mixed group of term and
preterm infants [85]. Caffeine therapy for apnoea of prematurity has been shown to reduce the rates of
cerebral palsy and cognitive delay; however, no long-term effects on survival without disability or sleep
apnoea have been found [86].
Evidence is now accumulating regarding the use of high-flow nasal cannula (HFNC) in the newborn
period. In a systematic review conducted by CHAKRABORTY et al. [87], data from a total of 1112 preterm
infants enrolled in randomised or quasi-randomised clinical trials were analysed showing similar efficacy
to other modes of noninvasive ventilation. As previously reported there was a significant reduction in the
incidence of nasal trauma with HFNC, but also a trend towards lower rates of air leaks and mortality. A
majority of the infants were born moderately to late preterm suggesting that, at least in this group of more
mature infants, the safety profile with less adverse effects is an advantage of HFNC. Interestingly, this is in
line with the preference of nursing staff according to a recent study in which nurses favoured nasal
continuous positive airway pressure (CPAP) as the choice of respiratory support post-extubation in the
most preterm infants, but preferred HFNC in infants >28 weeks gestation [88].
In very preterm infants, one of the most commonly used indications for HFNC in clinical practice is
weaning from CPAP in infants with evolving or established BPD. In a small cross-over study performed
around 2 weeks of age in preterm infants with an average gestational age of 27 weeks, SHETTY et al. [89]
reported no significant advantage with regard to work of breathing, thoracoabdominal asynchrony or
oxygen saturations with HFNC compared with CPAP. Evidence from YODER et al. [90] suggests that HFNC
is comparable to nasal CPAP in preventing extubation failure, but data on various other indications for
HFNC use is lacking. HFNC as the primary mode of respiratory support in preterm infants will be tested
the HIPSTER study, a randomised trial designed for noninferiority, and others studies are on the way [91].
Infection and immunity
Respiratory viral infections remain a major cause of morbidity and mortality worldwide. The importance
of neutrophils in the inflammatory response to respiratory viruses is now well known. While their role in
contributing to the severity of symptoms appears well established it is still unclear how important they are
in viral clearance. SAINT et al. [92] presented data from in vitro gene microarray experiments suggesting
that when neutrophils are exposed to the respiratory syncytial virus (RSV) a number of antiviral pathways
are activated. They concluded that this supported the suggestion that neutrophils play an important active
role in the innate antiviral response. FONSECA et al. [93] presented data from a rodent model of RSV
infection in which, as expected, the acute illness was characterised by an intense airways neutrophilia that
rapidly resolved. However, following these animals to 21 days post-infection there was persistence of viral
replication in airways dendritic cells although no virus was identifiable in BAL, suggesting that the virus
may be able to persist at low levels in these cells in vivo as well as in vitro. The same group also presented
evidence to support the suggestion that the virus may be acquired in utero [94]. Their study found
evidence of viral RNA in 60% of human cord blood monocytes and they speculated that in utero exposure
may have an impact on the host’s ability to mount an effective long-term memory response. Admissions
to hospital with acute bronchiolitis continue to place a considerable burden on health systems. BOYD et al.
[95] undertook a health economics assessment of changing the criteria for taking infants out of oxygen
using a threshold saturation of 90% in air rather than 94% and suggested that this would result in a saving
of approximately EUR 356 per patient without any compromise in safety. This does of course only apply
to infants whose saturation in air falls below 94% so cannot be extrapolated to all admissions, and it is
also important to remember this was undertaken in patients in whom the saturation data was being used
to inform when oxygen therapy should be discontinued, that is they were in the recovery phase of the
illness. Hence the results should not be extrapolated to the concept that any infant with saturations >90%
early in the course of the illness can be safely discharged. A Russian group presented data suggesting that
the use of recombinant α2-interferon administered once daily to children aged <3 years admitted with
respiratory viral infections resulted in more rapid resolution of inflammation and clearance of virus [96].
Prevention remains the goal of much of this research, but to date, there is no imminent prospect of an effective
vaccine entering routine practice. A large Canadian study retrospectively reviewed outcomes for more than
19000 infants who had been prescribed palivizumab for any reason enrolled over a 9-year period. They found
that, when compared with the 60% who received all five doses, health outcomes in those who were less
compliant were worse [97]. The increase in hospitalisation was relatively modest, but duration of hospitalisation
if admitted was markedly increased (7.8 versus 16.6 days). Effectively addressing the issues underlying low rates
of compliance remains one of the great challenges across the whole of healthcare. A second large study from
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the same group found no significant benefit could be identified among infants with CF given palivizumab
when compared with infants with CF who did not receive the humanised antibodies [98].
The study by KORTEN et al. [99] addressing the impact of rhinovirus infections on the nasopharyngeal
microbiota exemplified the potential of modern sequencing techniques to transform our understanding of
the interactions between the human host and microbiota occupying different niches within and on the
body, and how these interactions drive important components of health and disease. By sampling the
nasopharynx biweekly they confirmed that many rhinovirus infections were largely asymptomatic. Their
data indicates that symptomatic infections appear to be associated with lower bacterial diversity and higher
bacterial density, in large part supporting some earlier studies using conventional microbiology indicating
that density of bacterial pathogens is an important determinant of the severity of nasal symptoms in those
with an apparent viral “cold”. As in other studies, they found a degree of resilience within the microbiome
although the change might persist for up to 3 weeks. Frequent symptomatic infections did appear able to
produce more long lasting changes.
Studies addressing the potential for host factors to impact on these interactions included studies addressing
the structure and function of cilia. HIRST et al. [100] demonstrated electron microscopy changes in some
cilia from some patients with conditions included under the umbrella term ciliopathies (genetic disorders of
non-motile cilia) (figure 1). A multinational team used immunofluorescence to explore functional
correlates of genetic mutations in patients with PCD and proposed this approach would be valuable in
diagnosis of patients with loss-of-function mutations and missense variants [101]. Another condition
associated with significant respiratory morbidity is ataxia telangiectasia. DEVANEY et al. [102] highlighted the
delay in diagnosis of ataxia telangiectasia, although they were unable to identify an impact of this delay on
respiratory status. The potential of targeting host mediators in order to prevent disease progression was
again raised in a presentation in which the authors noted that ceramides detected in tracheal aspirates from
premature infants varied between those who developed chronic lung disease and those who did not [103].
A group from London presented data suggesting that aspiration was relatively common in apparently
normal children with chronic or recurrent respiratory problems [104]. Interestingly, there was apparently
no difference in the pattern of symptoms or severity in those in whom aspiration was judged to occur as
compared with those in whom it was considered that aspiration was not occurring.
FIGURE 1 Cystic cilia tip from
Sensenbrenners ciliopathy. Reproduced
from [100] with permission from the
author.
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Other groups addressed a range of infectious diseases. A group from Korea again highlighted the
importance of considering Chlamydia trachomatis as a cause of acute respiratory illness in infancy, with
the organism being identified in 8.3% of a very large cohort of infants with acute bronchiolitis [105]. The
potential use of novel technologies in directing management was raised by an exploratory study in which
MALDI-TOF mass spectrometry was used to characterise protein composition associated with
parapneumonic effusions [106]. The challenges of early diagnosis and instituting appropriate therapy for
hydatid disease even in areas in which it is endemic was again raised, with the authors noting that 18% of
subjects required lobectomy [107]. Research into pulmonary infections and host responses is entering an
exciting period as the power of “omics” technologies such as gene sequencing (16S rRNA and the more
complex “shotgun” sequencing) metabolomics and computational biology are brought into this area.
Viruses and asthma and the airway microbiome
The role of viruses in asthma pathogenesis and asthma symptoms remains a hot topic. In a symposium on
virus-driven and host-defence immune responses in acute virus-induced asthma James Gern (University of
Wisconsin, Madison, WI, USA) argued that allergic inflammation inhibits interferon responses to virus
infections, with rhinovirus C being the most prominent example. This was in line with a recent review by
LAMBRECHT et al. [108] on the immunology of asthma. In this review, reduced interferon production after
exposure to viral agents, due to interference with eosinophil-derived transforming growth factor-β and
upregulation of chitinases and chitinase-like proteins, was suggested to be related to increased
susceptibility to viruses in patients with asthma. According to James Gern, this decreased response may be
attenuated by omalizumab. He showed data that omalizumab reduces rhinovirus-induced asthma attacks
during the peak season and speculated that enhanced interferon-α production by omalizumab reduces
viral replication, thereby mitigating disease severity and exacerbation risk [109]. Whether inhaled
interferons may reduce or mitigate viral exacerbations in asthma remains to be seen.
Peter Le Soeuf (The University of Western Australia, Crawley, Australia) showed that viral infections are
associated with an altered airway microbiome, which may lead to a higher risk of viral infection and asthma.
Michael Cox (Imperial College, London, UK) showed that the airway microbiome is an equilibrium that can
be influenced by internal and external factors. Diseases may cause selection of the microbiome and asthma
severity seems to be associated with changes in the microbiome. However, in a small number of infants
diagnosed with wheeze, no significant differences were found in the airway microbiome between acute attacks
and during short-term follow-up. However, rhinovirus infections did change the bacterial copy numbers in
patients with chronic obstructive pulmonary disease and, not surprisingly, smoking alters the airway
microbiome. Studies on the influence of the airway microbiome on asthma development are scarce. A small
study in children suggested that microbiome characteristics modulate host inflammatory and immune systems
in patients with asthma [110]. TEO et al. [111] studied the nasopharyngeal microbiome during the first year of
life in 234 infants and looked at both viral and bacterial communities. Early asymptomatic colonisation with
Streptococcus strongly predicted asthma, and not surprisingly antibiotics disrupted the microbiome. The
authors suggest that the nasopharyngeal microbiome might offer preventive strategies to asthma development
by targeting pathogenic bacteria. Whether manipulation of the airway microbiome may offer new
opportunities to interfere with airways and lung diseases remains to be shown, but is a highly exciting area.
E-health in paediatric asthma
Two multicentre studies from the Netherlands assessed the effect of a text alert to improve adherence to
inhaled medication and of a virtual asthma clinic, respectively [112, 113]. With real-time medication
monitoring coupled with text reminders VASBINDER et al. [112] were able to improve adherence to treatment;
however, this did not result in better asthma control or asthma-related quality of life. Results were similar in
the UK, where an intervention using electronic monitoring with feedback (figure 2) did not improve asthma
control as assessed by the primary outcome, the Asthma Control Questionnaire (figures 3 and 4), although
secondary outcomes such as hospital admissions and oral steroid courses were reduced in the feedback
group [114]. Technical problems such as broken or lost devices were frequent in the intervention group.
JOCHMANN et al. [115] from London used Smartinhalers (Adherium Ltd, Auckland, New Zealand) to assess
adherence and showed that, despite the patients being aware that adherence was monitored, 58% of the
children used <80% of prescribed medication. Self-reported adherence (Medicine Adherence Rating Scale
questionnaire) did not reflect this and prescription uptake only weakly reflected electronically monitored
adherence. Asthma control measures improved in the children with moderate-to-good adherence to
treatment. The second Dutch study showed that replacing clinic visits with web-based contacts was
successful in the so-called virtual asthma clinic used by VAN DEN WIJNGAART et al. [113]. While reducing
clinic visits by 50% similar asthma control could be maintained by offering patients and their parents
web-based contacts. VOOREND-VAN BERGEN et al. [116] showed that a somewhat similar approach was
cost-effective. Fortunately adolescents and parents have a positive attitude to having their adherence
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measured and shared with healthcare providers, although the social acceptability of Smartinhalers needs
attention [117]. Although systematic reviews did not show an overall effect of e-health interventions on
asthma outcomes, careful analyses of studies that did show an effect can be helpful in determining which
interventions may be useful, in which populations, how often and how extensively [118].
Visualising the airway and lung
ANTÓN-PACHECO et al. [119] presented the long-term outcome and the quality of life of a group of children
with severe airway malacia who had undergone metallic stenting. Seven out of 23 patients had their stents
in place for more than 5 years. 13 metallic stents, one tracheal and 12 bronchial, were bronchoscopically
placed at median age of 5 months. Complications were fewer than expected. The impact on the quality of
life was considered as mild to moderate. KRIVEC et al. [120] also presented their experience with
therapeutic interventions in the airways during flexible bronchoscopy. In 37 patients (median age 2.8 years,
range 0.1–17.0 years) they performed 55 procedures, including large mucous plugs and bronchial cast
removals (39 procedures), foreign body extractions (nine procedures) and other airway occlusion
resolutions (one large laryngeal granulation, two subglottic membranes, one tracheal membrane and three
bronchial membranes). No serious complications were reported.
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FIGURE 3 Adherence over a year for the intervention (Smartinhaler feedback group; adherence=70% for the
whole 12 months) and control (normal care; adherence=49% for the whole 12 months) groups in a) the
morning and b) the afternoon. The boxes represent the interquartile range and the horizontal lines indicate
the median. Data from [114] with permission from the author.
FIGURE 2 Electronic adherence
monitor (Smartinhaler; Adherium,
Auckland, New Zealand). Image
courtesy of Mark L. Everard.
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In tracheomalacia, DOUROS et al. [121] studied the use of helical CT scans in 21 children with brassy cough
or, as they call it, “vibrating” cough (accompanied by a sense of vibration in the chest wall). All children
underwent fibre-optic bronchoscopy and tracheomalacia was confirmed in 19 children, who were further
investigated with helical CT. The cross-sectional area ratio of the trachea at the level of maximum
end-expiration collapse during end-expiration and end-inspiration (CSR), determined the basis for the
helical CT diagnosis. Four children who underwent helical CT scans for reasons unrelated to tracheomalacia
served as controls. Mean (95% CI) CSR was 0.59 (0.54–0.65) and 0.89 (0.78–0.98) in patients and controls,
respectively. Helical CT diagnosed tracheomalacia in four (21%), 13 (68%) and 17 (89%) patients, if the
criterion used was CSR ⩽0.5, CSR ⩽0.6 and CSR ⩽0.7, respectively. All the controls had CRS >0.7. The
authors proposed that CSR ⩽0.7 would be an appropriate threshold for tracheomalacia in children.
In a retrospective study, FASSEEH et al. [122] reviewed 97 infants (78.4% females) who were diagnosed with
subglottic haemangioma at Alexandria University Hospitals in Egypt from 2002 to 2012. The mean age of
onset and diagnosis were 2.8±1.1 and 5.6±1.7 months, respectively. It was noted that 87.6% of the cases
had biphasic stridor, 68% had grade 3 airway obstruction and 35.1% were associated with cutaneous
haemangiomas. Most of the cases received oral propranolol (52.6%), some received systemic steroids
(30.9%) and a few received both oral steroids and propranolol (16.5%). In the steroids group, 40% of the
cases showed a rapid response, 36.7% showed a slow response and 23.3% of cases did not respond to
treatment. The best response rate was noted in the propranolol group (98.0%) with a rapid or even very
rapid response to treatment without reported side-effects. In an interesting Spanish multicentre
retrospective study (involving 11 centres), MORENO et al. [123] presented data regarding the anatomical
and clinical characteristics of tracheal bronchus. 93 patients with tracheal bronchus diagnosed by
bronchoscopy (81.6%) and/or chest CT were included. All of them were right sided and 66% were in the
lower third of the trachea. Broncho-obstructive episodes (60.2%) were the predominant clinical
manifestation reported, whereas 44% had pneumonia. Children with tracheal bronchus were associated
with heart disease (39.7%), tracheomalacia (35.5%), gastro-oesophageal reflux (31%) and Down syndrome
(10.5%). Most of them (73%) had a favourable outcome.
WALKER et al. [124] investigated whether physician’s interpretation of gross findings in children with
persistent respiratory symptoms correlated with the information obtained during bronchoscopies they
underwent regarding the appropriate antibiotic prescription. They retrospectively audited the
bronchoscopic findings, BAL cell count and culture, and decision to commence antibiotics over a 3-month
period in one paediatric centre. 22 patients aged 1–15 years underwent bronchoscopy and BAL. The
commonest indication was persistent cough. These results gave a sensitivity of 84% and specificity of 57%
for the physician decision to initiate antibiotics based on macroscopic bronchoscopy findings. The authors
concluded that experienced physician decisions to initiate antibiotics based on bronchoscopy findings have
good sensitivity and result in the majority of patients receiving antibiotics appropriately.
Exercise-induced asthma is considered the most common cause of exertional dyspnoea, but other causes
such as cardiovascular or pulmonary diseases, poor fitness, hyperventilation and vocal cord dysfunction are
also implicated. However, a significant proportion of symptomatic adolescents do not fit into these
categories with symptoms of dysfunctional breathing limiting physical activity. BENZRATH et al. [125]
presented data on 59 adolescents with exercise-induced dysfunctional breathing other than exercise-induced
asthma. 45 patients showed dysfunctional breathing, but did not meet the criteria of hyperventilation or
vocal cord dysfunction. They were considered to have exercise-induced dyspnoea. Frequently there was a
history of competitive sport. Typically dyspnoea was accompanied by significant lactic acidosis and oxygen
desaturation, as in exercise-induced arterial hypoxaemia. Patients showed a typical breathing pattern, and
usually showed a good response to physiotherapy aiming at modification of the breathing pattern.
FIGURE 4 Asthma Control
Questionnaire (ACQ) scores for the
intervention and control groups. Data
from [114] with permission from the
author.
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The clinical utility of routine CT chest scanning is still debated, as CT scanning in young children often
requires sedation and the biological effects of radiation later in life are uncertain. Some still advocate for
routine annual surveillance, while most believe it should be restricted to clinical need on an individual
basis. Due to technical progress, the scanning time can be reduced to 0.4 s and radiation exposure can be
reduced further. This makes CT scanning possible during normal breathing (CT-b) without anaesthesia,
and has been investigated in infants with and without CF in the first year of life. All CT-b scans showed
good concordance between the two scores for air trapping (intraclass correlation coefficient=0.98). Infants
with CF showed a significant increase in air trapping score expressed as a z-score at 10 weeks and 1 year of
age [126]. Due to concerns over the radiation burden of CT scans, there is still an interest in the use of
magnetic resonance imaging (MRI) for long term monitoring of lung disease. Researchers from Heidelberg
investigated the correlation between MBW and MRI chest scores in children with CF and healthy subjects.
Morphological, perfusion and global MRI chest scores were elevated in stable CF children and were
positively correlated with a higher LCI z-score; the concordance between abnormal findings in MBW and
MRI was above 70% [127]. Both had worsening scores during an exacerbation, and significantly improved
after antibiotic therapy. However, use of MRI scanning in routine clinical practice seems unlikely given the
time, expense and the fact that sedation or general anaesthesia are required for younger patients.
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